Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.

导出 LinkOut

翻译打印收藏纠错

第一作者： Meijia,Qian

第一单位： Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

作者： Meijia,Qian ^[1] ; Fangjie,Yan ^[2] ; Weihua,Wang ^[1] ; Jiamin,Du ^[1] ; Tao,Yuan ^[1] ; Ruilin,Wu ^[1] ; Chenxi,Zhao ^[1] ; Jiao,Wang ^[1] ; Jiabin,Lu ^[1] ; Bo,Zhang ^[3] ; Nengming,Lin ^[3] ; Xin,Dong ^[4] ; Xiaoyang,Dai ^[1] ; Xiaowu,Dong ^[1] ; Bo,Yang ^[1] ; Hong,Zhu ^[5] ; Qiaojun,He ^[6]

作者单位： Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. ^[1] Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China. ^[2] Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China. ^[3] Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. ^[4] Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.;Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China.;Cancer Center of Zhejiang University, Hangzhou 310058, China. ^[5] Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.;Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China.;Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.;Cancer Center of Zhejiang University, Hangzhou 310058, China. ^[6]

关键词 CCA, cholangiocarcinoma Cholangiocarcinoma DAB, 3,3-diaminobenzidine tetrahydrochloride chromogen DUB, deubiquitinase Deubiquitinase FGFR, fibroblast growth factor receptor FOLFOX, folinic acid, 5-FU and oxaliplatin IDH1/2, isocitrate dehydrogenase 1/2 IHC, immunohistochemistry IP, immunoprecipitation JOSD2 KRAS, kirsten rat sarcoma 2 viral oncogene homolog LATS1/2, large tumor suppressor kinase 1/2 MST1/2, mammalian Ste20-like kinases 1/2 OTUB2, otubain-2 PBS, phosphate-buffered saline PDC, patient derived cell PDX, patient-derived xenograft RTV, relative tumor volume SRB, sulforhodamine B TAZ, transcriptional co-activator with PDZ-binding motif TCGA, The Cancer Genome Atlas USP9X/10/47, ubiquitin-specific peptidase 9X/10/47 YAP, Yes-associated protein YAP/TAZ YOD1, ubiquitin thioesterase OTU1 rhJOSD2, recombinant human JOSD2 shRNA, specific hairpin RNA

DOI 10.1016/j.apsb.2021.04.003

PMID 35024322

发布时间 2022-01-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Acta pharmaceutica Sinica. B

2021年11卷12期

4008-4019页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.

Acta pharmaceutica Sinica. B

相似文献

Acta pharmaceutica Sinica. B

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.

Acta pharmaceutica Sinica. B

相似文献

Acta pharmaceutica Sinica. B

相关期刊

检索历史清除